Stralem & Co. Inc. cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,490 shares of the medical research company’s stock after selling 4,245 shares during the quarter. Thermo Fisher Scientific comprises 2.4% of Stralem & Co. Inc.’s investment portfolio, making the stock its 28th biggest position. Stralem & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $13,954,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of TMO. Bank of Nova Scotia Trust Co. acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $106,000. Ropes Wealth Advisors LLC boosted its holdings in Thermo Fisher Scientific by 15.8% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares during the last quarter. Atlantic Trust LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $138,000. Acrospire Investment Management LLC boosted its holdings in Thermo Fisher Scientific by 66.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 400 shares during the last quarter. Finally, Glassman Wealth Services boosted its holdings in Thermo Fisher Scientific by 23.1% in the 2nd quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 195 shares during the last quarter. Hedge funds and other institutional investors own 86.25% of the company’s stock.
Shares of Thermo Fisher Scientific Inc. (NYSE TMO) traded up $2.74 during mid-day trading on Wednesday, hitting $210.75. 719,103 shares of the stock traded hands, compared to its average volume of 1,650,000. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc. has a 52-week low of $140.00 and a 52-week high of $211.81. The firm has a market cap of $84,070.00, a price-to-earnings ratio of 35.78, a P/E/G ratio of 1.71 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same period in the prior year, the business posted $2.03 EPS. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. analysts forecast that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, January 15th. Stockholders of record on Friday, December 15th were issued a $0.15 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
In other news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the transaction, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.49% of the company’s stock.
Several equities analysts have weighed in on the stock. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 target price on the stock. Evercore ISI assumed coverage on shares of Thermo Fisher Scientific in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 target price on the stock. Leerink Swann reiterated an “outperform” rating and issued a $200.00 target price (down from $216.00) on shares of Thermo Fisher Scientific in a report on Monday, December 4th. Finally, Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $212.21.
WARNING: “Stralem & Co. Inc. Sells 4,245 Shares of Thermo Fisher Scientific Inc. (TMO)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/17/stralem-co-inc-sells-4245-shares-of-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.